A quality ASX 200 share with 'limited to no impact' from Donald Trump's tariffs

A leading expert believes this ASX 200 company is now at an "attractive entry point".

If you're buying S&P/ASX 200 Index (ASX: XJO) shares, you'll have noticed some unwanted headwinds blowing out of the United States recently. 

Those headwinds come courtesy of United States President Donald Trump.

As you're likely aware, Trump has been slapping sizeable tariffs on his nation's biggest trading partners, including China, Canada, Mexico, the European Union and, yes, Australia.

Fears of a broadening global trade war have pressured global stock markets, sending the ASX 200 down 8.1% in a month.

And investors have been fairly indiscriminate in their selling, even pressuring ASX 200 shares with strong earnings and outlooks.

While that may cause some short-term pain for shareholders, it also creates an opportunity to buy quality, oversold companies.

"For the first time in a long time, it seems valuation matters," said Phil Cornet, a portfolio manager at Atlas Funds Management Australian Equity Income fund.

Asked about the recent ASX 200 sell-off, Cornet said (courtesy of The Australian Financial Review):

A sell-off forces investors to ask what is the right price? Good stocks are and will be caught up with overvalued stocks in the sell-off, which creates great opportunities for investors.

Stocks with solid earnings and strong balance sheets that pay regular dividends will endure and will be sought after when the calm returns.

Cropped shot of a young female scientist working on her computer in the laboratory.

Image source: Getty Images

An undervalued ASX 200 share

As for the most undervalued ASX 200 share his fund holds, Cornet named biotech stock CSL Ltd (ASX: CSL).

"CSL's share price has fallen 20% over the last six months despite selling largely non-discretionary lifesaving biotherapies," he said.

(At the time of writing, CSL shares are down 16% over six months.)

"We have been surprised at the sharemarket weakness after the company reported solid profit growth and a nice 16% increase in the dividend courtesy of a weaker Australian dollar," he added.

According to Cornet (quoted by the AFR):

The market ignored a typically good result from CSL's key immunotherapy business and an improvement in the oft-critiqued renal acquisition Vifor and instead focused on a soft flu vaccination period in the US earlier this year.

Atop its strong profit growth forecasts, Cornet is also bullish on CSL shares due to the company's relative immunity to Trump's tariff campaigns.

Cornet noted:

With management guiding to 10% to 13% profit growth in 2025 and the company selling a product that will have limited to no impact from Donald Trump's tariffs, CSL's current share price looks to be an attractive entry point.

And the ASX 200 share should catch some tailwinds from the weak Aussie dollar.

"The fact that it is an offshore earner is also appealing, given the weakness in the Australian dollar," Cornet concluded.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »